On June 23, 2020 Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, reported the closing of its previously announced upsized initial public offering of 12,650,000 of its common shares, including the exercise in full of the underwriters’ option to purchase up to an additional 1,650,000 common shares, at a public offering price of $20.00 per share (Press release, Repare Therapeutics, JUN 23, 2020, View Source [SID1234561400]). The gross proceeds to Repare, before deducting underwriting commissions and offering expenses, were $253.0 million. All of the common shares were offered by Repare.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Repare’s common shares are listed on the Nasdaq Global Select Market under the ticker symbol "RPTX."

Morgan Stanley, Goldman Sachs & Co. LLC, Cowen and Piper Sandler & Co. acted as joint book-running managers for the offering.

The shares were offered by Repare pursuant to a registration statement that was declared effective by the U.S. Securities and Exchange Commission ("SEC") on June 18, 2020. A prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov.

The offering of these shares was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone: 1-866-471-2526 or by emailing [email protected]; Cowen and Company, LLC c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at [email protected] or by telephone at (833) 297-2926; or Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at 800-747-3924 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of Repare’s common shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

On June 23, 2020 Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, reported the closing of its initial public offering of 15,964,704 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 2,082,352 additional shares of common stock, at a public offering price of $20.00 per share (Press release, Forma Therapeutics, JUN 23, 2020, View Source [SID1234561399]). The aggregate gross proceeds to Forma from the offering were approximately $319.3 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Forma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies, SVB Leerink and Credit Suisse acted as joint book-running managers for the offering.

Registration statements relating to these securities have been filed with the Securities and Exchange Commission ("SEC") and became effective on June 18, 2020. The offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected]; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6218, or by email at [email protected]; or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On June 23, 2020 Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, reported that it will report financial results for the quarter and fiscal year (FY) ended April 30, 2020 on June 30, 2020 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time) (Press release, Avid Bioservices, JUN 23, 2020, View Source [SID1234561398]). Members of Avid’s senior management will discuss financial results for the quarter and FY ended April 30, 2020 and review recent corporate developments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To listen to the live webcast, or access the archived webcast, please visit: View Source

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Avid Bioservices call.

On June 23, 2020 Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, reported that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of 38,888,892 of the Company’s ordinary shares represented by American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 19,444,446 ADSs, at a combined purchase price of $0.90 per ADS and associated warrant, in a registered direct offering, for aggregate gross proceeds of approximately $35.0 million (Press release, Kitov Pharmaceuticals , JUN 23, 2020, View Source [SID1234561397]). Each ADS represents one ordinary share, no par value, of Kitov. The offering is expected to close on or about June 25, 2020, subject to satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The warrants will have an exercise price of $0.90 per ADS and will be exercisable at any time upon issuance and will expire five years from the date of issuance.

Kitov intends to use the net proceeds of this offering to fund the development of its oncology drug candidates, acquisition of new assets and for general working capital purposes.

The securities described above are being offered by Kitov pursuant to a "shelf" registration statement on Form F-3 (File No. 333- 235327) previously filed with the U.S. Securities and Exchange Commission (the "SEC") on December 2, 2019 and declared effective by the SEC on December 13, 2019. The offering of such securities will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the securities being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at View Source or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (646) 975-6996 or e-mail at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

On June 23, 2020 Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, reported that the results of a Stanford study using its drug sensitivity screening platform have been published in Blood Advances (June 23, 2020; Volume 4, Issue 12) (Press release, Notable Labs, JUN 23, 2020, View Source [SID1234561396]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This study was designed to evaluate Notable’s drug sensitivity screening platform in patients with myelodysplastic syndrome (MDS) and related myeloid neoplasms. After piloting the platform in 33 patients, the authors conducted a prospective feasibility study, enrolling 21 MDS patients refractory to standard therapies: azacitidine (Vidaza) or decitabine (Dacogen). The primary endpoint of the study was to determine if the drug sensitivity results could be returned to a Tumor Board within a clinically actionable timeframe (<30 days) to inform personalized treatment recommendations. The study met its primary endpoint with drug sensitivity data provided to the Tumor Board at a median turnaround time of 15 days, and these data helped identify potentially useful drugs and drug combinations for MDS patients refractory to standard therapies. Among 21 patients who received a therapy that was tested in Notable’s platform, the authors demonstrated a positive predictive value of 92%, negative predictive value of 82%, and overall accuracy of 85% of the platform in predicting clinical responses.

Additional key details of the study are listed below:

54 patients were enrolled at Stanford University Medical Center between September 2016 and March 2019 and had a diagnosis of MDS, MDS/myeloproliferative neoplasm (MPN), or acute myeloid leukemia (AML).
Blood samples and bone marrow aspirate samples were provided to Notable Labs, and ex vivo drug sensitivity screening was performed using Notable’s fully automated high-throughput platform, evaluating sensitivity to a panel of 74 individuals drugs and 36 drug combinations.
Notable’s platform identified three groups of patients with distinct drug sensitivity patterns.
Correlations were observed between genotype and phenotype, with specific gene mutations associated with distinct drug sensitivity patterns.
Notable and Stanford are currently enrolling a second cohort of patients to validate the initial data set.

"We set out to explore whether this platform could produce accurate results in a timely manner, and the answer is yes," said Peter Greenberg, MD, Professor of Medicine (Hematology) and Director, Stanford MDS Center at Stanford University Cancer Center. "These data demonstrate the utility of this approach for identifying potentially useful and often novel therapeutic drugs for patients with myeloid neoplasms refractory to standard therapies."

"This peer-viewed research is a substantial clinical milestone for Notable and for precision medicine in oncology," said Laurie Heilmann, CEO of Notable. "One significant aspect of this research is the dataset Notable is amassing. Our bioinformatics and machine learning models are generating vast datasets that will help inform future drug development. These data are critical for biotech and pharma companies who want to accelerate their go-to-market. We look forward to working closely with Stanford to continue this important research."

In Jan. 2020, Notable announced the launch of its new observational clinical trial. The trial is being conducted at multiple sites across the country and will focus on hematologic malignancies (blood cancers). The primary objective is to establish a tumor registry with annotated clinical outcomes. Exploratory objectives will include correlation of ex vivo drug screening results with clinical outcomes as well as identification of potential biomarkers that correlate clinical responses with genotype and/or phenotype. More details on Notable’s Institutional Review Board-approved clinical trial is available at View Source